During the past decade, Presidio Ospedaliero Firenze Centro Piero Palagi conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Presidio Ospedaliero Firenze Centro Piero Palagi" are "Psoriasis" (4 trials). Many other conditions were trialed in "Presidio Ospedaliero Firenze Centro Piero Palagi" in a lesser frequency.

Most popular intervention types in "Presidio Ospedaliero Firenze Centro Piero Palagi" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Mirikizumab" (2 trials), "Guselkumab" (1 trials), "Placebo" (1 trials) and "Secukinumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Presidio Ospedaliero Firenze Centro Piero Palagi" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Presidio Ospedaliero Firenze Centro Piero Palagi". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Presidio Ospedaliero Firenze Centro Piero Palagi, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Presidio Ospedaliero Firenze Centro Piero Palagi, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".